Squamous Cell H&N Cancer Hypopharynx Therapeutic Approach Ricardo Hitt MD, PhD Hospital Universitario 12 Octubre MADRID STATEMENTS 2008

Squamous Cell H&N Cancer Hypopharynx  The majority of hypopharyngeal lesions originate in the pyriform sinus.  On admission, 75% of the patients have clinically positive nodes. clinically positive nodes.  There is no difference in the risk of neck metastases by T stage. metastases by T stage.

HN surgeon Decision making Medical oncologist Treatment of Head and Neck Cancer Multidisciplinary Radiation oncologist

Decision making CLINICAL TRIAL STANDARD TREATMENT Treatment of Head and Neck Cancer Multidisciplinary

HYPOPHARYNGEAL CANCER HEAD AND NECK CANCER OROPHARYNX ORAL CAVITY LARYNXHIPOPHARYNX

HYPOPHARYNGEAL CANCER OBJECTIVES CURE ORGAN PRESERVATION QUALITY OF LIFE

HYPOPHARYNGEAL CANCER TODAY,WITH MEDICAL TREATMENT ORGAN PRESERVATION OVERALL SURVIVAL NEW OBJECTIVEIncrease Overall Survival and Organ Preservation NEW OBJECTIVE: Increase Overall Survival and Organ Preservation HOW???

J. L. Lefebvre, D. Chevalier, B. Luboinski, L. Traissac, G. Andry, D. De Raucourt, L. Collette, J. Bernier, EORTC Head and Neck Cancer Cooperative Group. F R A N C E Is Laryngeal Preservation (LP) With Induction Chemotherapy (ICT) Safe in the Treatment of Hypopharyngeal SCC? Final Results of the Phase III EORTC Trial. Last Update: ASCO 2004

STUDY DESIGN Surgery + RT LP: PF + RT R Primary endpoint: OS (non-inferiority of LP) Secondary endpoints: PFS, larynx preservation Lefebvre JL, et al. JNCI 1996; 88:890-8; Lefebvre JL, et al. ASCO 2004: Abstract N = 94 N = 100 Cycle 1 PD* CR* PR* NC* Cycle 2 NC/PD* CR* PR*Cycle 3CR* PR/NC/PD* RXT 70 Gy ± salvage surgery Surgery + Postoperative RXT

Surgery (No CT) (N=94) (%) Larynx Preservation (N=100)(%) Stage Stage II67 Stage III5459 Stage IV3934 Site of primary Pyriform sinus7978 Aryepiglottic fold2122 PATIENT CHARACTERISTICS Lefebvre JL, et al. ASCO 2004: Abstract 5531.

(years) ONNumber of patients at risk : Surgery LP Overall survival Larynx preservation HR: 0.88 (95% CI: ) P= for non-inferiority of LP Surgery Median, 44 mo Median, 25 mo (years) ONNumber of patients at risk : Surgery Preservation Disease-free survival Larynx preservation Surgery Hazard Ratio: 0.83 (95% CI: ) Lefebvre JL, et al. ASCO 2004: Abstract OVERALL SURVIVAL AND DFS

Devita. 7th Edition SURVIVAL PHARYNGEAL SCC

Devita. 7th Edition SURVIVAL PHARYNGEAL SCC

Historical standard treatment (80') for locally advanced squamous cell carcinoma of the head and neck (SCCHN) Surgery  radiation (RT) Inoperable disease Operable disease Background RT (5 yr surv. 10%-20%) Concomitant CT/RT standard for inop. Pts (90’) (5yr surv. 20%- 30% )

35 previously untreated pts: 3 cycles cisplatin-5FU (CF) Response > 50% 94 % Complete response 63 % Decker D et al. ASCO Annual Meeting. Saint Louis 1982, Abstract C-757 Decker DA et al. Cancer 1983;51: tumors treated with platinum-based chemotherapy Ensley J et al. ASCO Annual Meeting. Saint Louis 1982, Abstract C-767 Ensley JF et al. Cancer 1984;54: responses > 50% 97 % after RT 18 responses < 50% 6%6% after RT ASCO 1982: The Platinum Revolution

Induction CT: high RR ( 70%-80%); RC (5% - 30%) 1- 4 cycles prior to RT Subsequent RT or surgery not compromised Not clear if local control increased Response to induction CT predicts response to RT Part of a larynx preservation strategy Rationale for induction CT -1-

Induction CT reduces incidence of distant metastases Patient selection crucial (dist.met. 30%-40%) T bulky ; N (bilateral, high number, capsula rupture), Site (hypopharynx), other markers From meta-analysis: induction with PF 5% incr. OS 5yr P= individual studies showed survival benefit with PF (GSTTC ; GETTEC) Rationale for induction CT -2-

Improved Complete Response Rate and Survival in Advanced Head and Neck Cancer After Three- Course Induction Therapy With 120-Hour 5-FU Infusion and Cisplatin MICHAEL ROONEY, MD,.t JULIE KISH, MD,JOHN JACOBS, MD.( JEANNIE KINZIE, MD,ARTHUR WEAVER, MD., JOHN CRISSMAN. MD. AND MUHYl AL- SARRAF. MD Cancer 55: I

MACH-NC Collaborative Group: Effect of Chemotherapy on 5-Year Survival Monnerat C, et al. Ann Oncol. 2002;13:995. [Review] Pignon JP, et al. Lancet. 2000;355:949. Meta-analyses of individual patient data from randomized trial that recruited patients from 1965 to 1993  PF induction conferred a 5% survival gain at 5-years  CRT conferred an 8% survival improvement at 5-years CRT=chemoradiotherapy; PF=cisplatin+5-FU. Trial CategoryNo. of TrialsNo. of PtsDifference, %p-Value All < Adjuvant Induction PF Other chemotherapy Concomitant CRT <0.0001

SCCHNC HOW CAN WE IMPROVE THESE RESULTS? Change the schedule of ICT Change the approach of treatment

Induction CT + Locoregional RT Remenar E, et al. ASCO 2006, abstract Bernier J, et al. ASCO 2006, abstract Vermorken JB, et al. ASCO 2004, abstract EORTC 24971/TAX Study Design Neck Dissection InoperableSCCHN Stage 3-4. Stratification: 1º tumor site Institution TPF arm (n=177) Docetaxel (75 mg/m²) Cisplatin (75 mg/m²) 5-FU (750 mg/m²/dx5) Q 3 weeks x 4 cycles PF arm (n=181) Cisplatin (100 mg/m²) 5-FU (1000 mg/m²/dx5) Q 3 weeks x 4 cycles Radiotherapy (~70 Gy over 7 weeks) Follow up Surgery for Residual Disease Treatment arms were well balanced in baseline characteristics Primary Objective: PFS

Overall Survival EORTC 24971/TAX 323 (months) Treatment PF TPF Remenar E, et al. ASCO 2006, abstract Bernier J, et al. ASCO 2006, abstract Vermorken JB, et al. ASCO 2004, abstract PFTPF Median OS, mo Hazard ratio (95% CI)0.71 (0.56, 0.90) P-value0.0055

Induction CT  CRT  Surgery Posner RM, et al. ASCO 2006, abstract SPS24. TAX Study Design Treatment arms were well balanced in baseline demographic and disease characteristics Primary Objective: Primary Objective: OS Radiotherapy (70Gy d1-5) + Weekly Carboplatin (AUC 1.5  7) Surgery is needed PF arm (n=246) Cisplatin (100 mg/m²/d1) 5-FU (1000 mg/m²/d  5) Q 3 weeks x 3 cycles TPF arm (n=255) Docetaxel (75 mg/m²) Cisplatin (100 mg/m²d1) 5-FU (1000 mg/m²/d  4) Q 3 weeks x 3 cycles N=538 Stage III/IV Epidermoidcarcinoma, no prior surgery, no hospitalization for COPD  1y Stratification: Center Center N status N status Primary site Primary site

Posner RM, et al. ASCO 2006, abstract SPS24. TAX Study Design Primary Endpoint: Overall Survival Year OS TPF 62% PF 48% 2-Year OS TPF 67% PF 54% Survival Time (months) Log-Rank p =.0058 Hazard ratio = 0.70 TPF (n=255) PF (n=246) TPF significantly improved overall survival vs PF 30% reduction in mortality Survival Probability (%)

HNSCC: Taxotere in Locally-Advanced Disease Posner et al. ASCO Remenaer et al., ASCO 2006 Overall Survival TPF PF TPF PF Survival Time (months) Survival Probability (%) Survival Time (months) TAX % reduction in risk of death TAX % reduction in risk of death

Hitt R, et al. ASCO 2006, abstract Phase III Trial PF ± Docetaxel  CRT vs CRT Study Design Primary endpoint phase III: TTF SCHNN Stage III, IV (locally advanced) Unresectable PF 3 cycles q 21 days  Cisplatin  Infusional 5-FU (N=440) TPF 3 cycles q 21 days  Docetaxel  Cisplatin  Infusional 5-FU CRT

Phase III Trial PF ± Docetaxel  CRT vs CRT RESPONSE RATE BY ARM TPF/CRT CRT CRT CR (complete response) 70 % % p = EFFICACY Hitt R, et al. ASCO 2006, abstract 5515.

Al Sarraf Cancer 1985 Does the Complete Response to Induction Chemotherapy/CRT have the same benefit in survival ?

CHEMORADIOTHERAPY HNC STANDARD TREATMENT STANDARD TREATMENT OLD STANDARD CRT GOLD STANDARD ICT/CRT

CONCLUSIONS (1)  Hypopharyngeal SCC has a bad prognostic with conventional treatment  The objective of treatment can be : cure-quality of life  For Medical Oncologist Hypopharyngeal Cancer= SCCHN  To day is possible Larynx Preservation without damage OS  Induction chemotherapy is feasible in a set of the patients  Chemoradiotherapy can be a Radical Treatment

CONCLUSIONS (2)  When is possible: Salvage Surgery is recommended  Now we have data about the superiority of TPF as ICT  Complete Response to TPF/CRT might be a parameter as overall survival  Induction TPF plus CRT might be the next standard  Selection of patients is the key for treatment selection RESECTABLE////UNRESECTABLE TUMORSRESECTABLE////UNRESECTABLE TUMORS